Drugs & Aging

, Volume 9, Issue 2, pp 122–147 | Cite as

Mitoxantrone

A Review of its Pharmacological Properties and Use in Acute Nonlymphoblastic Leukaemia
  • Christopher J. Dunn
  • Karen L. Goa
Drug Evaluation

Summary

Synopsis

Acute nonlymphoblastic leukaemia (ANLL) is a malignant condition strongly associated with advancing age. Of adult acute leukaemias, 80 to 85% are classified as ANLL, with more than half of all patients being aged over 60 years.

Although advancing age has been reported to be a poor prognostic factor in ANLL, recent clinical trials have shown good results in patients aged 60 years and over after coadministration of the anthracenedione antineoplastic agent mitoxantrone with cytarabine. In 1 study in particular, which involved patients aged 60 to 81 years, no correlation was found between increasing age and response rate. However, results of a major clinical trial showed age greater than 60 years to be associated with poorer outcomes.

Mitoxantrone as initial induction treatment is at least as effective as daunorubicin when either drug is given in combination with cytarabine to patients with previously untreated ANLL. Complete response rates in randomised comparative trials were 53 to 67% after mitoxantrone with cytarabine and 37 to 70% after daunorubicin with cytarabine. In a major US study, significantly more patients achieved a complete response after 1 treatment cycle of mitoxantrone and cytarabine than after daunorubicin and cytarabine. Mitoxantrone has also been effective in inducing complete remissions in patients with relapsed or refractory ANLL, mainly in combination with other antineoplastic agents.

Overall survival appears similar after treatment with regimens containing either mitoxantrone or daunorubicin in patients with ANLL, although there have been reports of trends towards increased survival rates with mitoxantrone.

The incidence of cardiotoxicity appears low in patients with ANLL who have received mitoxantrone. Lower cardiotoxicity of mitoxantrone relative to daunorubicin has not been conclusively demonstrated in patients with ANLL, although trials in patients with breast cancer have shown mitoxantrone to cause fewer cardiac adverse effects than doxorubicin. This is of particular interest in the elderly, as this group of patients is especially susceptible to the effects of anthracycline-induced cardiac toxicity.

Thus, mitoxantrone is a suitable first-line agent for the induction of remission in patients with ANLL, with clearly demonstrated efficacy in patients aged 60 years and over.

Pharmacodynamic Properties

Mitoxantrone is believed to exert its cytotoxic effects by interfering with the function of topoisomerase II (thereby preventing religation of DNA strand breaks). The drug may also inhibit protein kinase C activity and may enhance induce apoptosis in leukaemic cells.

Mitoxantrone is active against a variety of tumour systems (both leukaemias and solid tumours). Additive or synergistic effects in inducing cellular DNA damage are obtained when cells are exposed to mitoxantrone in combination with cytarabine, amsacrine, cisplatin, doxorubicin, etoposide and a number of other agents. Enhanced cellular damage has also been reported after sequential exposure to mitoxantrone and cytarabine.

Overview of Pharmacokinetic Properties

After intravenous administration, mitoxantrone has a rapid distribution (α) phase of up to approximately 10 minutes’ duration and a subsequent β phase which lasts for up to approximately 3 hours. The drug has a very large volume of distribution (1000 to 4000L). Animal data suggest that the extent of plasma protein binding is 78%. In patients with acute nonlymphoblastic leukaemia (ANLL), mitoxantrone appears to be concentrated in leukaemic cells.

Mitoxantrone is thought to be metabolised by the liver and eliminated mainly in bile. Renal clearance accounts for up to approximately 10% of the total clearance of the drug. The terminal elimination (γ) half-life of mitoxantrone has been reported to be 1 to 215 hours; the precise nature and duration of this phase remain to be defined.

Therapeutic Use of Mitoxantrone in Acute Nonlymphoblastic Leukaemia

Complete response rates of 48 to 83% were reported in noncomparative trials in patients with previously untreated ANLL, most of whom received mitoxantrone 10 mg/m2/day for 3 to 5 days with cytarabine 100 to 200 mg/m2/day for 5 to 7 days (all results reported in this section were obtained after intravenous administration). Notably, no correlation was demonstrated between patient age and response in one of these studies which involved patients aged 60 to 81 years.

Mitoxantrone and daunorubicin showed similar efficacy in terms of rates of complete response and survival in comparative clinical trials where either drug was coadministered with cytarabine. Complete response rates were 53 to 67% for mitoxantrone-treated patients and 37 to 70% for those who received daunorubicin. Differences between groups were statistically nonsignificant, but there was a trend towards increased response rates with mitoxantrone in 3 of 4 trials. In a major comparative US study, poorer complete response rates were seen in patients aged over 60 years than in younger patients after either mitoxantrone and cytarabine or daunorubicin and cytarabine. Significantly more patients achieved complete remission after 1 treatment cycle with mitoxantrone than with daunorubicin in this trial.

Preliminary data from a meta-analysis of 6 clinical studies in 1020 patients with ANLL have shown complete response rates of 57% in patients who received induction chemotherapy with mitoxantrone and cytarabine, compared with 50% in those who received daunorubicin and cytarabine. Five-year overall and disease-free survival was similar for both regimens.

Mitoxantrone 10 mg/m2/day plus etoposide 100 mg/m2/day for 5 days resulted in complete response rates of 50 to 57% in 3 trials in patients with previously untreated ANLL, 2 of which involved only patients aged 60 years and over. The addition of cytarabine further improved the complete response rate (to 64 to 74%).

Patients with relapsed or refractory ANLL have also responded to treatment with mitoxantrone, given either as monotherapy or in combination with other agents. Clinical trials of mitoxantrone monotherapy (10 to 14 mg/m2/day for 3 to 5 days) resulted in complete response rates of 32 to 48%. Complete response rates of 28 to 67% were recorded in studies ranging in size from 15 to 151 patients after salvage chemotherapy with mitoxantrone and cytarabine, with incomplete cross-resistance between mitoxantrone and daunorubicin or doxorubicin being reported in some trials. In a randomised study of 151 patients in which patients were stratified according to age (< years or ≥60 years), there was no significant difference in response between age groups. Complete response rates of 16 to 61 % after coadministration of mitoxantrone with etoposide, and 33 to 66% after mitoxantrone with cytarabine plus etoposide, have been reported in patients with relapsed or refractory ANLL.

Attempts have been made to enhance the cytotoxicity of mitoxantrone and other cytotoxic agents in patients with ANLL by ‘priming’ leukaemic bone marrow with granulocyte colony-stimulating factors before administering chemotherapy. However, the results of these small studies are inconclusive.

Tolerability

Leucopenia, the major dose-limiting adverse effect of mitoxantrone chemotherapy, is of particular concern in elderly patients. Comparative data have shown similar granulocyte recovery times after chemotherapy with cytarabine plus either mitoxantrone or daunorubicin (median 30 and 33 days, respectively, to attain granulocyte counts ≥1000/µ1 in one study). Platelet recovery times were also similar for these 2 regimens. No significant difference between treatment groups in the number of deaths secondary to hypoplastic or aplastic marrow was observed after either mitoxantrone or daunorubicin with cytarabine in a major comparative US trial. These results also showed no statistically significant effect of age on aplastic death rates after treatment with mitoxantrone or daunorubicin, although there was a trend towards higher death rates in patients aged 60 years and over.

Studies in patients with breast cancer have shown significantly less cardiotoxicity with mitoxantrone than with doxorubicin. The incidence of cardiotoxicity appears low in patients with ANLL who have received mitoxantrone; a major comparative trial reported a similar incidence of congestive heart failure (CHF) [mainly attributable to fluid overload due to supportive therapy] after treatment with cytarabine plus either mitoxantrone or daunorubicin. Anthracyclines show cumulative cardiotoxicity, and patients treated with mitoxantrone are stated to have a cumulative 2.6% probability of developing clinical CHF after a cumulative dose of 140 mg/m2.

Other nonhaematological adverse effects associated with mitoxantrone therapy include nausea and vomiting, diarrhoea, abdominal pain, stomatitis, infections and alopecia. Comparative data have shown the incidence of these and other effects to be similar in patients with ANLL after treatment with regimens incorporating either mitoxantrone or daunorubicin.

Dosage and Administration

Mitoxantrone should be given at a dosage of 12 mg/m2/day on days 1 to 3 of treatment, together with a continuous infusion of cytarabine 100 mg/m2/day on days 1 to 7. The concentrated aqueous solution of mitoxantrone should be diluted to at least 50ml with sodium chloride 0.9%, dextrose 5% or dextrose 5% with sodium chloride 0.9% and introduced into a freely running intravenous infusion over not less than 3 minutes.

Keywords

Adis International Limited Etoposide Cytarabine Mitoxantrone Acute Myeloid Leukaemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Faulds D, Balfour JA, Chrisp P, et al. Mitoxantrone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991 Mar; 41: 400–49PubMedGoogle Scholar
  2. 2.
    Johnson PRE, Hunt LP, Yin JA. Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival. Br J Haematol 1993 Oct; 85: 300–6PubMedGoogle Scholar
  3. 3.
    Murdock KC, Child RG, Fabio PF, et al. Antitumor agents. 1. l,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones. J Med Chem 1979; 22(9): 1024–30PubMedGoogle Scholar
  4. 4.
    Capranico G, Zunino F. DNA topoisomerase-trapping antitumour drugs. Eur J Cancer 1992; 28A(12): 2055–60PubMedGoogle Scholar
  5. 5.
    Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351–75PubMedGoogle Scholar
  6. 6.
    Wang JC. DNA topoisomerases: why so many? J Biol Chem 1991 Apr 15; 266(11): 6659–62PubMedGoogle Scholar
  7. 7.
    Wang JC. DNA topoisomerases. Annu Rev Biochem 1985; 54: 665–97PubMedGoogle Scholar
  8. 8.
    Fox ME, Smith PJ. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the DNA intercalators mAMSA and mitoxantrone. Cancer Res 1990 Sep 15; 50: 5813–8PubMedGoogle Scholar
  9. 9.
    Capranico G, De Isabella P, Tinelli S, et al. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II. Biochemistry 1993 Mar 30; 32: 3038–46PubMedGoogle Scholar
  10. 10.
    Kolodziejczyk P, Reszka K, Lown JW. Enzymatic oxidation activation and transformation of the antitumor agent mitoxantrone. Free Radic Biol Med 1988; 5: 13–25PubMedGoogle Scholar
  11. 11.
    Fisher GR, Patterson LH. DNA strand breakage by peroxidase-activated mitoxantrone. J Pharm Pharmacol 1991; 43: 65–8PubMedGoogle Scholar
  12. 12.
    Bowden GT, Roberts R, Alberts DS, et al. Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene. Cancer Res 1985 Oct; 45: 4915–20PubMedGoogle Scholar
  13. 13.
    Gorczyca W, Bigman K, Mittelman A, et al. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia 1993 May; 7: 659–70PubMedGoogle Scholar
  14. 14.
    Ray S, Ponnathpur V, Huang Y, et al. 1-β-D-arabinofuranosylcytosine-, mitoxantrone-, and paclitaxel-induced apoptosis in HL-60 cells: improved method for detection of internucleosomal DNA fragmentation. Cancer Chemother Pharmacol 1994 Aug; 34: 365–71PubMedGoogle Scholar
  15. 15.
    Takeuchi N, Nakamura T, Takeuchi F, et al. Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells. J Biochem Tokyo 1992 Dec; 112: 762–7PubMedGoogle Scholar
  16. 16.
    Bhalla K, Ibrado AM, Tourkina E, et al. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood 1993 Nov 15; 82: 3133–40PubMedGoogle Scholar
  17. 17.
    Chandrasekaran B, Dimling J, Capizzi RL. Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin. Cancer Treat Rep 1987 Feb; 71: 195–6PubMedGoogle Scholar
  18. 18.
    Schabel Jr FM, Corbett TH, Griswold Jr DP, et al. Therapeutic activity of mitoxantrone and ametantrone against murine tumors. Cancer Treat Rev 1983; 10Suppl. B: 13–21PubMedGoogle Scholar
  19. 19.
    Grant S, Arlin Z, Gewirtz D, et al. Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blast progenitors. Leukemia 1991 Apr; 5: 336–9PubMedGoogle Scholar
  20. 20.
    Satyamoorthy K, Chitnis MP, Pradhan SG, et al. Modulation of mitoxantrone cytotoxicity by verapamil in human chronic myeloid leukemia cells. Oncology 1989; 46: 128–31PubMedGoogle Scholar
  21. 21.
    Chitnis MP, Satyamoorthy K, Pradhan SG, et al. Modulation of sensitivity to mitoxantrone in human chronic myeloid leukemia cells by the antidepressant sintamil. Oncology 1988; 45: 292–6PubMedGoogle Scholar
  22. 22.
    Juvekar AS, Chitnis MP, Advani SH. In vitro modulation of adriamycin and mitoxantrone cytotoxicity by hyperthermia and diazepam, in human chronic myeloid leukemia cells. Neoplasma 1987; 34: 199–204PubMedGoogle Scholar
  23. 23.
    Juvekar AS, Chitnis MP, Adwankar MK, et al. Effect of mitoxantrone on human chronic myeloid leukemia cells in vitro, combined with hyperthermia. Neoplasma 1986; 33: 477–82PubMedGoogle Scholar
  24. 24.
    Kano Y, Suzuki K, Akutsu M, et al. Effects of mitoxantrone in combination with other anticancer agents on a human leukemia cell line. Leukemia 1992 May; 6: 440–5PubMedGoogle Scholar
  25. 25.
    Vogel CL. Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer: a review. Semin Oncol 1995 Apr; 22Suppl. 5: 61–5PubMedGoogle Scholar
  26. 26.
    Rosenthal CJ, Ibrahim A, Rambhia H, et al. Paclitaxel (Taxol)-mitoxantrone salvage therapy in metastatic carcinoma of the breast — phase I/II study [abstract no. 172]. In: Perry MC, editor. Proceedings of the Thirtieth Annual Meeting of the American Society of Clinical Oncology; 1994 May 14–17; DaGoogle Scholar
  27. 27.
    Krehmeier C, Zühlsdorf M, Büchner T, et al. Synergistic cytotoxicity of cytosine arabinoside and mitoxantrone for K562 and CFU-GM. Hamatol Bluttransfus 1990; 33: 129–32Google Scholar
  28. 28.
    Fountzilas G, Inoue S, Ohnuma T. Schedule-dependent interaction of cytarabine plus doxorubicin or cytarabine plus mitoxantrone in acute myelocytic leukemia cells in culture. Leukemia 1990 May; 4: 321–4PubMedGoogle Scholar
  29. 29.
    Heinemann V, Murray D, Walters R, et al. Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemother Pharmacol 1988; 22: 205–10PubMedGoogle Scholar
  30. 30.
    Gerlach JH, Kartner N, Bell DR, et al. Multidrug resistance. Cancer Surv 1986; 5(1): 25–46PubMedGoogle Scholar
  31. 31.
    Multidrug resistance in cancer [editorial]. Lancet 1989 Nov 4; 2: 1075–6Google Scholar
  32. 32.
    Kamath N, Grabowski D, Ford J, et al. Overexpression of P-glycoprotein and alterations in topoisomerase-II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone. Biochem Pharmacol 1992 Sep 1; 44: 937–45PubMedGoogle Scholar
  33. 33.
    Michieli M, Damiani D, Geromin A, et al. Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia. Eur J Haematol 1992 Feb; 48: 87–92PubMedGoogle Scholar
  34. 34.
    Ludescher C, Eisterer W, Hilbe W, et al. Low frequency of activity of P-glycoprotein (P-170) in acute lymphoblastic leukemia compared to acute myeloid leukemia. Leukemia 1995 Feb; 9: 350–6PubMedGoogle Scholar
  35. 35.
    Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, et al. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeolid leukemia. Clin Cancer Res 1995 Jan; 1: 81–93PubMedGoogle Scholar
  36. 36.
    Marie JP, Helou C, Thevenin D, et al. In vitro effect of P-glycoprotein (P-gp) modulators on drug sensitivity of leukemic progenitors (CFU-L) in acute myelogenous leukemia (AML). Exp Hematol 1992 Jun; 20: 565–8PubMedGoogle Scholar
  37. 37.
    Pincus R, Goldman ID. Evidence for impaired mitoxantrone and vinblastine binding in P388 murine leukemia cells with multidrug resistance. Biochem Pharmacol 1990 Dec 15; 40: 2625–35PubMedGoogle Scholar
  38. 38.
    Laurent G, Bailly JD, Skladanowski A, et al. Natural resistance of acute myeloid leukemia to mitoxantrone: role of drug transport, topoisomerase II activity, and cell death pathway [abstract no. 2067]. Blood 1995 Nov 15; 86(10) Suppl. 1: 520aGoogle Scholar
  39. 39.
    Juvekar AS, Chitnis MR Circumvention of drug resistance of P388/R cells by the combination of adriamycin and mitoxantrone with hyperthermia (42°C). Neoplasma 1991; 38: 207–11PubMedGoogle Scholar
  40. 40.
    Sargent J, Elgie A, Alton P, et al. In vitromodification of resistance to MDR-related drugs in acute myeloid leukaemia (AML) [abstract]. Br J Cancer 1994 Jun; 69: 1192–3Google Scholar
  41. 41.
    Parekh H, Chitnis M. Differential alteration of cellular lipids in drug sensitive and resistant P388 leukemia cells by clofibrate: effects on mitoxantrone cytotoxicity. Tumori 1991 Apr; 77: 105–11PubMedGoogle Scholar
  42. 42.
    Kornblau SM, Andreeff F, Koller C, et al. Double anthracycline (mitoxantrone + idarubicin) therapy with cyclosporin A (CSA) to block multidrug resistance (MDR) as salvage therapy for relapsed or refractory acute myelogenous leukemia (R-AML) [abstract no. 2043]. Blood 1995 Nov 15; 86(10) Suppl. 1: 514aGoogle Scholar
  43. 43.
    Kornblau SM, Estey E, Consoli U, et al. A phase I study of mitoxantrone + VP-16 with multidrug (MDR) blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia (R-AML) [abstract no. 2044]. Blood 1995 Nov 15; 86(10) Suppl. 1: 514aGoogle Scholar
  44. 44.
    Ehninger G, Schuler U, Proksch B, et al. Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet 1990 May; 18: 365–80PubMedGoogle Scholar
  45. 45.
    Hulhoven R, Dumont E, Harvengt C. Plasma kinetics of mitoxantrone in leukemic patients. Med Oncol Tumor Pharmacother 1984; 1(3): 201–4PubMedGoogle Scholar
  46. 46.
    Gruber A, Liliemark J, Tidefelt U, et al. Pharmacokinetics of mitoxantrone in plasma and leukemic cells during treatment of patients with acute non-lymphocytic leukemia. Leuk Lymphoma 1992 Apr; 6: 493–6Google Scholar
  47. 47.
    Schleyer E, Kamischke A, Kaufmann CC, et al. New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites. Leukemia 1994 Mar; 8: 435–40PubMedGoogle Scholar
  48. 48.
    Alberts DS, Peng YM, Bowden GT, et al. Mechanism of action and pharmacokinetics of Novantrone® in intravenous and intraperitoneal therapy. In: ColtmanJr CA, editor. The current status of Novantrone®: Proceedings of a Symposium held March 21–24, 1985, at Scottsdale, Arizona. New York: Park Row Publishers, 1985: 15–21Google Scholar
  49. 49.
    Alberts DS, Peng Y-M, Leigh S, et al. Disposition of mitoxantrone in cancer patients. Cancer Res 1985; 45: 1879–84PubMedGoogle Scholar
  50. 50.
    Ehninger G, Proksch B, Heinzel G, et al. Clinical pharmacology of mitoxantrone. Cancer Treat Rep 1986; 70: 1373–8PubMedGoogle Scholar
  51. 51.
    Smyth JF, Macpherson JS, Warrington PS, et al. The clinical pharmacology of mitozantrone. Cancer Chemother Pharmacol 1986; 17: 149–52PubMedGoogle Scholar
  52. 52.
    Van Belle SJP, de Planque MM, Smith IE, et al. Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. Cancer Chemother Pharmacol 1986; 18: 27–32PubMedGoogle Scholar
  53. 53.
    Stewart DJ, Green RM, Mikhael NZ, et al. Human autopsy tissue concentrations of mitoxantrone. Cancer Treat Rep 1986; 70: 1255–61PubMedGoogle Scholar
  54. 54.
    Burns CP, Haugstad BN, North JA. Membrane transport of mitoxantrone by L1210 leukemia cells. Biochem Pharmacol 1987 Mar 15; 36: 857–60PubMedGoogle Scholar
  55. 55.
    Greidanus J, de Vries EGE, Mulder NH, et al. A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone. J Clin Oncol 1989; 7: 790–7PubMedGoogle Scholar
  56. 56.
    Ehninger G, Proksch B, Heinzel G, et al. The pharmacokinetics and metabolism of mitoxantrone in man. Invest New Drugs 1985; 3(2): 109–16PubMedGoogle Scholar
  57. 57.
    Azuno Y, Kaku K, Fujita N, et al. Mitoxantrone and etoposide in breast milk [letter]. Am J Hematol 1995 Feb; 48: 131–2PubMedGoogle Scholar
  58. 58.
    Chiccarelli FS, Morrison JA, Cosulich DB, et al. Identification of human urinary mitoxantrone metabolites. Cancer Res 1986; 46: 4858–61PubMedGoogle Scholar
  59. 59.
    Miser JS, Malspeis L, Staubus AE, et al. Plasma pharmacokinetics of mitoxantrone in pediatric patients. Proc Am Assoc Cancer Res 1983; 24: 132Google Scholar
  60. 60.
    McCauley DL. Treatment of adult acute leukemia. Clin Pharm 1992 Sep; 11: 767–96PubMedGoogle Scholar
  61. 61.
    Devine SM, Larson RA. Acute leukemia in adults: recent developments in diagnosis and treatment. CA Cancer J Clin 1994; 44: 11–2Google Scholar
  62. 62.
    Mastrianni DM, Tung NM, Tenen DG. Acute myelogenous leukemia: current treatment and future directions. Am J Med 1992; 92: 286–95PubMedGoogle Scholar
  63. 63.
    Liu Yin JA. Acute myeloid leukaemia in the elderly: biology and treatment. Br J Haematol 1993; 83: 1–6PubMedGoogle Scholar
  64. 64.
    Champlin RE, Gajewski JL, Golde DW. Treatment of acute myelogenous leukemia in the elderly. Semin Oncol 1989 Feb; 16(1): 51–6PubMedGoogle Scholar
  65. 65.
    Rees JKH, Gray RG, Swirsky D, et al. Principal results of the Medical Research Council’s 8th Acute Myeloid Leukaemia trial. Lancet 1986 Nov 29; 2: 1236–41PubMedGoogle Scholar
  66. 66.
    Feldman EJ. Acute myelogenous leukemia in the older patient. Semin Oncol 1995 Feb; 22Suppl. 1: 21–4PubMedGoogle Scholar
  67. 67.
    Phillips GL, Reece DE, Shepherd JD, et al. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 1991 Apr 1; 77(7): 1429–35PubMedGoogle Scholar
  68. 68.
    Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Blood 1990 Jan 1; 75(1): 27–32PubMedGoogle Scholar
  69. 69.
    Liu-Yin JA, Johnson PR, Davies JM, et al. Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. Br J Haematol 1991 Nov; 79: 415–20PubMedGoogle Scholar
  70. 70.
    MacCallum PK, Rohatiner AZS, Davis CL, et al. Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients. Ann Hematol 1995 Jul; 71: 35–9PubMedGoogle Scholar
  71. 71.
    Rodríguez-Morales A, López JL, Sánchez P, et al. Mitoxantrone (MTZ) and ARA-C: high remission rate as first line therapy for acute myeloid leukemia (AML) [abstract no. 499]. 5th International Symposium on Therapy of Acute Leukemias; 1991; Rome, Italy.Google Scholar
  72. 72.
    Samir Motawy M, Salfiti R, Khalifa F, et al. Experience with combinations containing mitoxantrone in the treatment of adult acute leukemias. J Chemother 1989 Apr; 1: 123–7PubMedGoogle Scholar
  73. 73.
    Arlin Z, Case Jr DC, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 1990 Mar; 4: 177–83PubMedGoogle Scholar
  74. 74.
    Bueno J, Herrero E, López A, et al. Treatment of acute myeloid leukemia (AML) in old patients [abstract no. 516]. 5th International Symposium on Therapy of Acute Leukemias; 1991; Rome, Italy.Google Scholar
  75. 75.
    Pavlovsky S, Gonzalez Llaven J, Garcia Martinez MA, et al. A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia. Ann Hematol 1994; 69: 11–5PubMedGoogle Scholar
  76. 76.
    Wahlin A, Hörnsten P, Hedenus M, et al. Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia. Cancer Chemother Pharmacol 1991 Oct; 28: 480–3PubMedGoogle Scholar
  77. 77.
    Bow EJ, Sutherland JA, Kilpatrick MG, et al. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J Clin Oncol 1996 Apr; 14(4): 1345–52PubMedGoogle Scholar
  78. 78.
    Ehninger G, Fackler-Schwalbe E, Freund M, et al. Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia. Hamatol Bluttransfus 1990; 33: 316–7Google Scholar
  79. 79.
    Knauf WU, Berdel WE, Ho AD, et al. Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia. Leuk Lymphoma 1994 Feb; 12: 421–5PubMedGoogle Scholar
  80. 80.
    Seiter K, Feldman E, Beer M, et al. Phase II study of high dose mitoxantrone-based induction therapy in patients with acute myeloid leukemia [abstract]. Blood 1995 Nov 15; 86(10) Suppl. 1: 780aGoogle Scholar
  81. 81.
    Shepherd JD, Barnett MJ, Brockington DA, et al. Induction and consolidation therapy with intermediate-dose cytarabine, mitoxantrone and etoposide in patients ≥ 60 years with acute myeloid leukemia (AML) [abstract]. Blood 1995 Nov 15; 86(10) Suppl. 1: 522aGoogle Scholar
  82. 82.
    Visani G, Petti MC, Cenacchi A, et al. MEC (mitoxantrone, etoposide and intermediate dose cytarabine): and effective induction regimen for previously untreated acute non-lymphocytic leukemia. Leuk Lymphoma 1995 Nov; 19: 447–51PubMedGoogle Scholar
  83. 83.
    Björkholm M, Liliemark J, Gahrton G, et al. Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia. A randomized comparison. Eur J Haematol 1995 Jul; 55: 19–23PubMedGoogle Scholar
  84. 84.
    Wheatley K. Meta-analysis of randomized trials of idarubicin (IDAR) or mitoxantrone (MITO) versus daunorubicin (DNR) as induction therapy for acute myeloid leukaemia (AML) [abstract no. 1724]. Blood 1995 Nov 15; 86(10) Suppl. 1Google Scholar
  85. 85.
    Feldman EJ, Alberts DS, Arlin Z, et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993 Oct; 11: 2002–9PubMedGoogle Scholar
  86. 86.
    Feldman E, Seiter K, Linker C, et al. Intensive induction without consolidation in elderly patients with newly diagnosed acute myeloid leukemia (AML)[abstract no. 1004]. In: Perry MC, editor. Proceedings of the Thirty-First Annual Meeting of the American Society of Clinical Oncology; 1995 May 20–23; Los Angeles.Google Scholar
  87. 87.
    Paciucci PA, Davis RB, Holland JF, et al. Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia. Am J Clin Oncol Cancer Clin Trials 1990 Dec; 13: 516–9Google Scholar
  88. 88.
    Archimbaud E, Leblond V, Michallet M, et al. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood 1991 May 1; 77: 1894–900PubMedGoogle Scholar
  89. 89.
    Walters RS, Kantarjian HM, Keating MJ, et al. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer 1988 Aug 15; 62: 677–82PubMedGoogle Scholar
  90. 90.
    Bezwoda WR, Bernasconi C, Hutchinson RM, et al. Mitoxantrone for refractory and relapsed acute leukaemia. Cancer 1990 Aug 1; 66: 418–22PubMedGoogle Scholar
  91. 91.
    Coccia-Portugal MA, Falkson G, Uys A. Mitoxantrone in the treatment of acute leukemia. Hamatol Bluttransfus 1990; 33: 318–21Google Scholar
  92. 92.
    Larson RA, Daly KM, Choi KE, et al. A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. J Clin Oncol 1987 Mar; 5: 391–7PubMedGoogle Scholar
  93. 93.
    Vredenburgh JJ, McIntyre OR, Cornwell III GG, et al. Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia. Med Pediatr Oncol 1988; 16: 187–9PubMedGoogle Scholar
  94. 94.
    Brito-Babapulle F, Catovsky D, Newland AC, et al. Treatment of acute myeloid leukemia with intermediate-dose cytosine arabinoside and mitoxantrone. Semin Oncol 1987 Jun; 14 (2 Suppl. 1): 51–2PubMedGoogle Scholar
  95. 95.
    Harousseau JL, Milpied N, Briere J, et al. Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia. Nouv Rev Fr Hematol 1990; 32(4): 227–30PubMedGoogle Scholar
  96. 96.
    Hiddemann W, Aul C, Maschmeyer G, et al. High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison. Leuk Lymphoma 1993; 10 Suppl.: 133–7PubMedGoogle Scholar
  97. 97.
    Hiddemann W, Kreutzmann H, Straif K, et al. Phase I/II trial of high-dose cytosine arabinoside and mitoxantrone in adult refractory acute myeloid leukemia. Hamatol Bluttransfus 1987; 30: 336–8Google Scholar
  98. 98.
    Keskin A, Tombuloglu M, Atamer MA, et al. Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia. Acta Haematol 1994; 92(1): 14–7PubMedGoogle Scholar
  99. 99.
    Liang R, Chiu E, Chan TK, et al. Salvage chemotherapy containing moderate-dose cytosine arabinoside and mitoxantrone for relapsed and resistant acute myeloid leukaemia. Cancer Chemother Pharmacol 1991 Apr; 28: 74–6PubMedGoogle Scholar
  100. 100.
    MacCallum PK, Davis CL, Rohatiner AZS, et al. Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence. Leukemia 1993 Oct; 7: 1496–9PubMedGoogle Scholar
  101. 101.
    Paciucci PA, Cuttner J, Holland JF. Sequential intermediate-dose cytosine arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia. Am J Hematol 1990 Sep; 35: 22–5PubMedGoogle Scholar
  102. 102.
    Paciucci PA, Dutcher JP, Cuttner J, et al. Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia. Leukemia 1987 Jul; 1: 565–7PubMedGoogle Scholar
  103. 103.
    Martiat P, Ghilain JM, Ferrant A, et al. High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study. Eur J Haematol 1990 Sep; 45: 164–7PubMedGoogle Scholar
  104. 104.
    O’Brien S, Kantarjian H, Estey E, et al. Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia. Cancer 1991 Aug 15; 68: 691–4PubMedGoogle Scholar
  105. 105.
    Daenen S, Löwenberg B, Sonneveld P, et al. Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard injection therapy and intermediate-dose cytarabine with amsidine. Leukemia 1994 Jan; 8: 6–10PubMedGoogle Scholar
  106. 106.
    Ho AD, Lipp T, Ehninger G, et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia—an active and well-tolerated regimen. J Clin Oncol 1988 Feb; 6: 213–7PubMedGoogle Scholar
  107. 107.
    Lazzarino M, Morra E, Alessandrino EP, et al. Mitoxantrone and etoposide — an effective regimen for refractory or relapsed acute myelogenous leukemia. Eur J Haematol 1989 Nov; 43: 411–6PubMedGoogle Scholar
  108. 108.
    Rowe JM, Mazza JJ, Hines JD, et al. Mitoxantrone and etoposide in patients with relapsed and refractory acute nonlymphocytic leukemia. Hamatol Bluttransfus 1990; 33: 326–9Google Scholar
  109. 109.
    Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 1991 Jul; 9: 1210–4PubMedGoogle Scholar
  110. 110.
    Archimbaud E, Thomas X, Leblond V, et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 1995 Jan; 13: 11–8PubMedGoogle Scholar
  111. 111.
    Björkholm M, Björnsdottir J, Stenke L, et al. Mitoxantrone, etoposide and cytarabine in the treatment of acute non-lymphocytic leukemia. Oncology 1990; 47: 112–4PubMedGoogle Scholar
  112. 112.
    Björkholm M. Mitoxantrone, etoposide and cytarabine in the treatment of acute myelocytic leukemia (AML). Haematol Bluttransfus 1994; 36: 216–20Google Scholar
  113. 113.
    Link H, Freund M, Diedrich H, et al. Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia. Haematol Bluttransfus 1990; 33: 322–5Google Scholar
  114. 114.
    Spadea A, Petti MC, Fazi P, et al. Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia. Leukemia 1993 Apr; 7: 549–52PubMedGoogle Scholar
  115. 115.
    Amrein PC, Davis RB, Mayer RJ, et al. Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase-I study. Am J Hematol 1990 Oct; 35: 80–3PubMedGoogle Scholar
  116. 116.
    Ohno R, Tomonaga M, Kobayashi T, et al. Effect of granulocyte-colony stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990; 323(13): 871–7PubMedGoogle Scholar
  117. 117.
    Archimbaud E, Fenaux P, Reiffers J, et al. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. Leukemia 1993 Mar; 7: 372–7PubMedGoogle Scholar
  118. 118.
    Mantovani L, Kämpfe D, Lehmann P, et al. Treatment of poor-prognosis AML with rhGM-CSF and rhG-CSF for priming, followed by cytarabine plus mitoxantrone induction therapy: a phase I/II study[abstract no. 3062]. Blood 1995 Nov 15; 86(10) Suppl. 1Google Scholar
  119. 119.
    Benjamin RS. Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Semin Oncol 1995 Feb; 22 (1 Suppl. 1): 11–3PubMedGoogle Scholar
  120. 120.
    Crossley RJ. Clinical safety and tolerance of mitoxantrone. Semin Oncol 1984 Sep; 11(3) Suppl. 1: 54–8PubMedGoogle Scholar
  121. 121.
    Mather FJ, Simon RM, Clark GM, et al. Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies. Cancer Treat Rep 1987 Jun; 71(6): 609–13PubMedGoogle Scholar
  122. 122.
    Posner LE, Dukart G, Goldberg J, et al. Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 1985; 3: 123–32PubMedGoogle Scholar
  123. 123.
    Immunex Corporation. Mitoxantrone for injection concentrate. Prescribing information. Seattle, Washington, USA, 1994.Google Scholar
  124. 124.
    Paxton A. Comment: mitoxantrone [letter]. Drug Intell Clin Pharm 1986 Jun; 20: 507–8Google Scholar
  125. 125.
    Leyden MJ, Sullivan JR, Cheng ZM, et al. Unusual side effect of mitoxantrone [letter]. Med J Aust 1983 Nov 12; 2: 514PubMedGoogle Scholar
  126. 126.
    Immunex Corporation. Mitoxantrone for injection concentrate. Technical monograph. Seattle, Washington, USA, 1994.Google Scholar
  127. 127.
    Dorr RT, Alberts DS, Soble M. Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone. Cancer Chemother Pharmacol 1986; 16: 91–4PubMedGoogle Scholar
  128. 128.
    Peters FTM, Beijnen JH, ten Bokkel Huinink WW. Mitoxantrone extravasation injury [letter]. Cancer Treat Rep 1987; 71(10): 992–3PubMedGoogle Scholar
  129. 129.
    Ketelby JW. Cytotoxic-drug extravasation [letter]. Med J Aust 1989 Jan 2; 150(1): 52Google Scholar
  130. 130.
    Man A. Local tissue damage as a result of extravasation of mitozantrone [letter]. BMJ 1986 Jul 12; 293: 140Google Scholar
  131. 131.
    Spataro V, Cometta A, Glauser MP, et al. Should elderly patients with acute myeloid leukemia be treated by myelosuppressive chemotherapy? [in German]. Schweiz Med Wochenschr 1995 Mar 4; 125: 429–32PubMedGoogle Scholar
  132. 132.
    Buechner T, Hiddemann W. Treatment strategies in acute myeloid leukemia (AML). Blut 1990; 60: 61–7PubMedGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Christopher J. Dunn
    • 1
  • Karen L. Goa
    • 1
  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations